SOURCE: PURE Bioscience, Inc

Pure Bioscience, Inc

October 22, 2013 08:30 ET

PURE Bioscience to Host Year End Results Conference Call October 24, 2013

New Management Team Discussion of Refocused Business Strategy

SAN DIEGO, CA--(Marketwired - Oct 22, 2013) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, October 24, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time). In addition to reviewing fiscal year end 2013 financial results, the purpose of this call is to:

  • Introduce the new management team,
  • Outline the Company's refocused business strategy in the food safety arena, and
  • Discuss steps being taken to restore PURE's financial condition.

PURE intends to file its Form 10-K on the October 24th after the close of the stock market.

The Participant Dial-In Number for the conference call is 1-412-902-6720. Participants should dial in to the call at least five minutes before 2:00 pm PDT (5:00 pm EDT) on October 24, 2013. The call can also be accessed "live" online at

A replay of the webcast will be available at as well as on the Company's website ( Also, a replay of the conference call will be available by dialing 1-877-870-5176 (international participants dial 1-858-384-5517) starting October 24, 2013, at 8:00 PM Eastern Time through December 8, 2013 at 11:59 pm Eastern Time. Please use PIN Number 91024.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

Forward-looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "expect," "intend," "project" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact Information

  • Contact:
    IR Contacts:
    Tom Hemingway
    Redwood Investment Group
    Email Contact

    Terri MacInnis, Director of IR
    Bibicoff + MacInnis, Inc.
    Email Contact

    Company Contact:
    Peter C. Wulff, CFO & COO
    PURE Bioscience, Inc.
    619-596-8600 ext.111
    Email Contact